A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib

Part of paid clinical trials in Buffalo, New York.

Sponsor
GlaxoSmithKline
Study ID
NCT00513253
Phase
PHASE1
Status
Withdrawn

Conditions

  • Healthy Subjects

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • lapatinib — DRUG

Study Details

This study is designed to estimate the relative bioavailability of alternative lapatinib oral formulations compared to the current tablet formulation.

Key Dates

Start date
Apr 30, 2008
Status verified
Feb 2015
Primary completion
May 31, 2008
Completion
May 31, 2008

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Primary Outcome Measure

Plasma levels for lapatinib will be done at: [ Time Frame: Day 1, Day 2, Day 3 for each Treatment Period ]

Locations (1)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteBuffaloNew York14202-

Find similar trials in Buffalo, NY

By research site
GSK Investigational Site· Buffalo, NY

Related Studies